Serotonin Activates S6 Kinase in a Rapamycin-Sensitive Manner in *Aplysia* Synaptosomes

Asad Khan, Antonio M. Pepio, and Wayne S. Sossin

*Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada*

The identification of tags that can specifically mark activated synapses is important for understanding how long-term synaptic changes can be restricted to specific synapses. The maintenance of synapse-specific facilitation in *Aplysia* sensory to motor neuron cultures can be blocked by inhibitors of translation and by the drug rapamycin, which specifically blocks a signaling pathway that regulates phosphorylation of translational regulators. One important target of rapamycin is the phosphorylation and subsequent activation of S6 kinase. To test whether S6 kinase is the target for the ability of rapamycin to block synapse-specific facilitation in *Aplysia*, we cloned *Aplysia* S6 kinase, its substrate S6, and the S6 kinase phosphoinositide-dependent kinase 1 (PDK-1). Serotonin, which induces synapse-specific facilitation, increased phosphorylation of *Aplysia* S6 kinase at threonine 399 in a rapamycin-sensitive manner in *Aplysia* synaptosomes. The phosphorylation of threonine 399 by 5-HT was independent of phosphoinositide-3 kinase, dependent on PKA and PKC, and occluded by the phosphatase inhibitor calyculin-A. 5-HT also increased S6 kinase activity and led to increased phosphorylation of S6 in synaptosomes. 5-HT increased levels of S6 in synaptosomes because of a rapamycin-sensitive increase in translation—stabilization of S6. *Aplysia* PDK-1 bound to and phosphorylated *Aplysia* S6 kinase but only modulated phosphorylation of threonine 399 indirectly. These results suggest a mechanism by which the levels of translation factors can be increased specifically at activated synapses generating a long-lasting synaptic tag.

**Key words:** synaptic plasticity; S6 kinase; *Aplysia*; synaptic tagging; rapamycin; serotonin; phosphoinositide-dependent protein kinase; S6; translation

S6 kinase activation requires multiple phosphorylation events that are regulated in a complex manner (Dufner and Thomas, 1999). Important sites in the inhibitory C terminus (Han et al., 1995) are similar to those phosphorylated by FRAP in eukaryotic initiation factor 4E binding protein (eIF4E-BP) and may be direct targets of FRAP (Gingras et al., 1998; Isotani et al., 1999). Phosphorylation of a threonine in the activation loop of S6 kinase is critical for activation; this site is phosphorylated by phosphoinositide-dependent kinase 1 (PDK-1) (Alessi et al., 1998; Pullen et al., 1998; Weng et al., 1998). Phosphorylation of another site, often called the PDK-2 site, is also required for S6 kinase activation (Pearson et al., 1995). Phosphorylation at this site is tightly linked with activation of the kinase and is the most sensitive to rapamycin (Pearson et al., 1995; Weng et al., 1998). Although there is some evidence that this site is phosphorylated by FRAP (Burnett et al., 1998a; Isotani et al., 1999), rapamycin sensitivity may also occur through FRAP-mediated inhibition of a calyculin-sensitive phosphatase (Dennis et al., 1996; Peterson et al., 1999; Westphal et al., 1999). These regulatory steps have been examined in cell lines; however, there is little data regarding the mechanism of activation of S6 kinase in neurons.

We have cloned S6 kinase in *Aplysia* to determine whether it may play a role in the rapamycin-sensitivity of long-term facilitation. We find that 5-HT increased S6 kinase phosphorylation at the PDK-2 site in synaptosomes and that this activation is blocked by rapamycin but not by PI-3 kinase inhibitors. Activation of S6 kinase leads to an increase in phosphorylation and levels of the S6 protein, suggesting that 5-HT may induce a synapse-specific increase in the production of translation factors in *Aplysia* through activation of S6 kinase.
Animals. *Aplysia californica* (75–125 gm) were obtained from Marine Specimens Unlimited (Pacific Palisades, CA) or University of Miami National Institutes of Health *Aplysia* resource facility (Miami, FL) and maintained in an aquarium for at least 3 d before experimentation. The animals were first placed in a bath of isotonic MgCl₂–artificial seawater (1:1, v/v) and then anesthetized by injection with isotonic MgCl₂ solution. The pharmacological agents LY294002, Chelerythrine, KT5720, calyculin-A, and rapamycin were purchased from Calbiochem (La Jolla, CA).

Cloning of *S6* kinase, PDK, and *S6*. To create *Aplysia* nervous system cDNA, pleural, pedal, and abdominal ganglia were dissected from the animals, immediately frozen in liquid nitrogen, and then processed using the Qiagen RNasy protocol (Qiagen, Santa Clara, CA) to obtain total RNA. cDNA template was made using Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD). Finally, cDNA product was used as a template in PCR to amplify fragments of *S6*, *S6* kinase, and PDK-1 using degenerate primers (see below). These fragments were cloned using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). The cloned fragments were labeled with [³²P]ATP using PCR and used to screen a 4-ZAP cDNA library (gift of Dr. J. H. Schwartz, Columbia University College of Physicians and Surgeons, New York, NY). From this screen, cDNAs containing the full coding region of *S6* and *S6* kinase were isolated, but for PDK-1, the longest clone isolated was missing a small fragment of the 3' end and this fragment could not be cloned from this library. To isolate the 3' end, we used 3' rapid amplification of cDNA ends (RACE) using nested primers from the sequenced clone and nested primers from the vector sequences of a plasmid cDNA library (Bartsch et al., 1993). This screen resulted in isolation of the 3' stop codon and addition of the PDK-1 3' untranslated region. All sequencing was done on both strands using the services of The W. M. Keck Biotechnology Resource Laboratory (Yale University, New Haven, CT) and Bio S&T Inc. (Montreal, Quebec, Canada). The sequences have been submitted to the GenBank database with accession numbers AF294916 (*S6* kinase), AF294917 (PDK), and AF294185 (*S6*). The following primers were used: *S6* kinase degenerate 5' primer (YAFOF), 5'-TAYGCNNYYCAYCARAC- 3'; *S6* kinase degenerate 3' primer (KPF1), 5'-ATRYTTCGCYMN- 3'; *S6* degenerate primer (KYG1), 5'-AARCARGGGNTTYCC- 3'; *S6* degenerate primer (KEDDV), 5'-AARGGNYTNTTYGC- 3'; PDK-1 degenerate 3' primer (KGEIPW), 5'-CCANGGDATYTCNCTTCCYT- 3'; PDK-1 degenerate 3' primer (KGLFA), 5'-AARGGNYTNTTYGC- 3'; PDK-1 degenerate 3' primer (KEIPW), 5'-CCANGGDATYTCNCTTCCYT- 3'; PDK-1 5' primer 1 3' RACE, 5'-TTGTGGAGGACAACTTGTCAAGAAAGC- 3'; PDK-1 5' primer 2 3' RACE, 5'-CCGCGAGGCAGCAGCACAGTC- 3'; PDK-1 (K-N) O5, 5'-CCACCAGGTCTCHGAGCAAGAC- 3'; PDK-1 (K-N) 15, 5'-CCACCAGGTCTAGGCAAGAGCCACAT- 3'; PDK-1 (K-N) 13, 5'-ACCATATTATTCTTGACCTAT- 3'; PDK-1 (K-N) O3, 5'-CGATTATCTTCCGGTGTCCGCAC- 3'.

Cloning of *PDK*. To make a baculovirus transfer vector for *S6* kinase, we cut the cDNA clone with *PstI* and *XhoI* and inserted it into BB4 at the BamHI site. To generate a baculovirus for PDK-1, we used a triple ligation cutting the long PDK-1 clone with *BamHI* and *DraI* fragment with *BstEI* and inserting these two fragments into BB4 cut with *BamHI* and *DraI*, the clone containing the 3' fragment with *DraI* and *KpnI*, and inserting these two fragments into BB4 cut with *BamHI* and *KpnI*. Mutating the catalytic lysine in PDK-1 was done with a two-step mutagenic procedure using PCR. First-round PCR used PDK-1 in BB4 as template and either the outside 5' primer (O5) and the inside 3' primer (I5) or the inside 3' primer (I5) and the outside 3' primer (O3) (see above for primers). The products from the first-round synthesis were combined and used as the template for second-round synthesis using O5 and O3. The resultant product was cut with *BstEI* and *DraHI* and inserted into PDK-1 in the BB4 vector. A new *Asel* was formed by the mutagenesis and was used to confirm the cloning. A fragment of PDK-1 containing the kinase domain, the PH domain, and ~75% of the unconserved 5' domain (starting at residue 130) was used to make a glutathione S-transferase (GST) fusion protein by cutting out both PDK-1 and PDK-1 (K-N) from the BB4 vector with *NcoI* and *MfeI*, filling in the ends with *Klenow*, and inserting the fragments into the *pGEX* 5x-1 (Amersham Pharmacia Biotech, Arlington Heights, IL) vector cut with *SmaI*. A GST-S6 fusion protein was made by cutting *S6* out of the cDNA clone with *EcoRI* and inserting it into *pGEX* 3.1 (Amersham Pharmacia Biotech) cut with *EcoRI*.

Production of antibodies. A peptide from *S6* kinase (CNGYDT- SAGCDMT-NHL) or PDK-1 (FFKYEQVW-KYRDYDAS-COOH) containing a cysteine residue added to the N terminal was synthesized and then coupled to both BSA maleimide and SulfoLink columns (Pierce, Rockford, IL). The coupled peptides were injected into rabbits with Titer-Max (CytRx, Norcross, GA) adjuvant four times at intervals of 1 month. The resultant sera were affinity purified over the SulfoLink columns and concentrated to at least 1 mg/ml. For *S6*, the antigen was the *S6* fusion protein. The resultant sera recognized only the *S6* doublet on Western blots and was not additionally purified.

Immunoblots. Western blots were performed as described previously (Dyer et al., 1996) with the *S6* kinase antibody at 2 µg/ml dilution, the *PDK* antibody at 2 µg/ml, the phosphopeptide antibody to the *PDK*-2 site (1 µg/ml; New England Biolabs, Beverly, MA), and goat anti-rabbit, horseradish peroxidase-conjugated secondary antibody at 1 µg/ml. The New England Biolabs antibody was incubated overnight at 4°C, whereas all other primary antibodies were incubated at room temperature for 2 hr. Blots were then developed with ECL (Amersham Pharmacia Biotech).

Expression of *S6* kinase, PDK, and *PI-3* kinase in *SP9* cells. Transfer vectors for *S6* kinase, PDK, and *PI-3* kinase were recombined with wild-type baculovirus (Invitrogen), and high titer stocks were prepared. For insect cell infection, a median of 5 for each virus was used. When multiple viruses were used in a single experiment, the same MOI was used, but double (or triple for three virus infections) amounts of protein was loaded onto gels for quantitation.

*PI-3* kinase assays. Supernatant and membrane fractions from *SP9* cells were incubated with mixed phosphoinositides (Sigma, St. Louis, MO) and 10 µM ATP (1 µCi of [γ-³²P]ATP) in 10 mm HEPES buffer. The lipids were then extracted and spotted by thin layer chromatography next to markers generated using purified *PI-3* kinase. Infec- tion with the activated form of *PI-3* kinase led to a 10- to 50-fold increase in levels of phosphoinositide (3,4,5) P3 generated from membranes of *SP9* cells (data not shown).

Phosphorylation of *S6* and *S6* kinase in synaptosomes. Synaptosomes were prepared as described previously (Chin et al., 1994). The protocol gives a P1 pellet containing particulate proteins, two soluble fractions (S2 and S3), and two synaptosome-containing fractions, P3, which contains the purest synaptosomes, and P2, which contains the greatest amount of synaptosomes but of lesser purity (Chin et al., 1989). Initially, P2 and P3 fractions were tested separately but, because no differences were observed in the amount of *S6* or *S6* kinase phosphorylated (data not shown), later experiments used a combination of P2 and P3. Synaptosomes, prepared from four to five nervous systems were used for single experiments, usually aliquoted into 8–12 individual tubes. All conditions were done in duplicate. An initial time course with 5-HT suggested that a 20 min incubation was optimal for increased threonine 399 (Thr 399) phosphorylation and 25 min for *S6* phosphorylation (data not shown). All experiments for *S6* kinase phosphorylation used a 20 min incubation with 5-HT and for all experiments with *S6* used 25 min. We have only used one concentration of 5-HT (20 µM). We have previously used this concentration to induce rapamycin-sensitive translational changes in *Aplysia* ganglia (Yanow et al., 1998), and it is similar to concentrations used to induce the rapamycin-sensitive change at *Aplysia* synapses (Casadio et al., 1999). Pharmacological inhibitors were applied at the same time as 5-HT. At the end of the time period, sample buffer was added to the synaptosomes, and they were boiled at 90°C for 5 min. Nine percent SDS-page gels were run until the 46 kDa marker was at the bottom of the gel to optimize separation of the post-translationally modified *S6* kinase. Blots were first probed with the anti-phospho-protein antibody and then probed for *S6* kinase. Twelve percent SDS gels were run until the dye reached the end of the gel for quantitation of *S6* because we were unable to resolve both post-translational modifications in the same gel system.

Quantitation of synaptosome phosphorylation. All gels were scanned and quantitated using NIH Image using the uncalibrated optical density function. We have found that this leads to a broad range in which results are linear (Nakhost et al., 1999). We standardized the phosphopeptide immunoactivity with the *S6* kinase immunoreactivity for each lane. Duplicates for each condition were then averaged, and the percentage change from control was calculated: ((experimental – control)/control) * 100. To calculate the effect of 5-HT, the percentage change from pharmacological agent alone was calculated. For *S6*, the percentage of upper band was calculated from the two well separated bands. Total *S6* was standardized to ponczeau stains of total protein to ensure gels were equally loaded with protein. Duplicates for each condition were then
averaged, and the percentage change from control was calculated: ((
experimental - control)/control) * 100. All statistical tests were paired 
t tests between control and experimental values.

S6 kinase assays. Synaptosomes were treated with low Ca2+-seawater 
or low Ca2+-seawater and 20 µM 5-HT for 20 min. The synaptosomes 
were lysed with immunoprecipitation buffer (1% Triton X-100, 150 mM 
NaCl, 0.5 mM 2-mercaptoethanol, 20 mg/ml aprotinin, 5 mM benzama-
dine, 0.1 mM leupeptin, 50 mM NaF, 5 mM sodium pyrophosphate, pH 
8.5, 1 mM microcystin, and 50 mM Tris, pH 7.8). Nonsolubilized proteins 
were spun out at 100,000 g, and the supernatant was incubated with 
anti-S6 kinase serum (5 µl) or preimmune serum (5 µl) that had been 
precoupled to protein-A beads. The beads were then spun down and 
washed extensively, and buffer was changed to kinase buffer (50 mM Tris, 
 pH 7.5, and 10 mM MgCl2). Substrate peptides derived from the 
Aplysia S6 sequence (see below) were added (20 µM), and the reaction was 
started with [32P]ATP (1 µCi, 50 µM final concentration). Supernatants 
were placed on phosphocellulose filters and washed with 1% cold ATP 
and then four times with 0.25% phosphoric acid before scintillation 
counting.

S6 peptides for assay. We synthesized two peptides based on the two 
putative S6 kinase sites (R/KxR/KxxS/T) in 
Aplysia S6 (RKRANSRA and RRAKGDSIA). These peptides were slightly modified from the S6 
sequences (RRKNSRKS and RSKGDSIA). We added positive charges at 
the N terminus of the second peptide to ensure binding to phosphocellu-
lulose papers. We also converted serines outside the S6 kinase site to 
alanine to reduce cross-reactivity with other kinases.

RESULTS
Cloning of Aplysia S6, S6 kinase, and PDK-1
To determine whether phosphorylation of S6 is a target for the 
rapamycin-sensitive pathway in Aplysia, we cloned Aplysia S6, S6 
kine, and the S6 kinase kinase PDK-1 (Alessi et al., 1998; 
Pullen et al., 1998). Using degenerate primers based on sequence 
homology between vertebrate and invertebrates, we isolated frag-
ments of the proteins and then used these fragments as a probe to 
screen an Aplysia cDNA library. Several clones were isolated for 
each protein and, based on mapping, the longest isolate was 
completely sequenced on both strands. For S6 and S6 kinase, the 
entire open reading frame was encoded on the sequenced clone 
(Fig. 1, 2). For PDK-1, this clone was lacking the 3' end of the 
PH domain and the stop codon, and further screening of the 
library did not result in longer clones. Therefore, we used 3' 
RACE to isolate an additional fragment that contained a stop 
codon to give the entire open reading frame (Fig. 3).

The sequence of S6 kinase contained an initiator methionine 
with a classic Kozak sequence preceded by a stop codon in frame, 
identifying it as the initiator methionine (data not shown). This
sequence is clearly an S6 kinase based on strong homology to vertebrate and invertebrate S6 kinases (47% identity to rat S6 kinase) (Fig. 1). The S6 kinase sequence contains many of the conserved phosphorylation sites that have been identified in S6 kinase, including the PDK-1 site, the PDK-2 site, a site preceding the PDK-2 site that is an autophosphorylation site in PKCs, and a serine–proline site in the autoinhibitory domain (Fig. 1). There is also conservation of an acidic region in the N-terminal domain thought to be important for rapamycin sensitivity (Fig. 1). One difference between the Aplysia S6 kinase and the vertebrate forms is the number of C-terminal phosphorylation sites; Aplysia has only one, whereas vertebrates have more than four sites in this region (Fig. 1). Also, the binding site for the PDZ-containing protein neurabin in the C terminal of S6 kinase (Burnett et al., 1998b) is not conserved in Aplysia. Drosophila and Caenorhabditis elegans S6 kinases also have fewer S/T-P sites in the C terminus and also lack the neurabin-binding site (Stewart et al., 1996; The C. elegans Sequencing Consortium, 1998).

The sequence of S6 stopped shortly after the initiating methionine. However, the high homology to other S6 proteins allowed
S6 kinase is enriched in synaptosomes; 10 μg S6 kinase. No immunoreactivity is seen in uninfected SF9 cells. Antibody in S6 kinase (Burnett et al., 1998b). Using gels optimized for separation (H, homogenate; P1, P2, P3, and S2) were loaded on a gel and blotted for S6 kinase. The fraction most enriched for synaptosomes (P3) contained the highest levels of S6 kinase. C. Optimizing gel separation and running time reveals multiple immunoreactive bands in ganglia (20 μg of homogenate) and band(s) in SF9 cells that comigrate with the faster migrating band(s) from nervous system.

Characterization of S6 kinase

An antibody was raised to a C-terminal peptide from the non-conserved C-terminal domain of S6 kinase. The antibody recognized a single band migrating at ~60 kDa in both SF9 cells expressing Aplysia S6 kinase and Aplysia ganglia (Fig. 4A). Because the physiological response to rapamycin was seen in Aplysia synapses, we next determined whether S6 kinase was detected in synaptosomes. Indeed, we found that S6 kinase was present in synaptosomes (Fig. 4B), similar to the distribution of vertebrate S6 kinase (Burnett et al., 1998b). Using gels optimized for separation in this region, there are multiple bands recognized by this antibody in Aplysia ganglia (Fig. 4C). These multiple bands probably consist of differentially phosphorylated forms of S6 kinase, similar to vertebrate S6 kinase (Dufner and Thomas, 1999). S6 kinase expressed in SF9 cells comigrates with the lower bands, consistent with reduced phosphorylation of the protein when overexpressed in SF9 cells (Fig. 4C).

5-HT increases phosphorylation of threonine 399 in a rapamycin-sensitive, PI-3 kinase-insensitive manner

To determine whether 5-HT could activate S6 kinase, we used a commercial anti-phosphopeptide antibody to the mammalian PDK-2 site Thr 399 in Aplysia, because this site is highly conserved (Fig. 1) and studies have suggested that it is most closely linked with S6 kinase activity (Weng et al., 1998). Indeed, this antibody recognized a band that corresponded to the size of the highest band observed with the total S6 kinase antibody (Fig. 5A). Treating synaptosomes with 5-HT induced a specific increase in the band recognized by the anti-phosphopeptide antibody (Figs. 5A, quantitated in 6A). Importantly, rapamycin significantly reduced immunoreactivity with the anti-phosphopeptide antibody (Figs. 5A, quantitated in 6A). Rapamycin also blocked the ability of 5-HT to increase phosphorylation of S6 kinase at Thr 399 (Figs. 5A, quantitated in 6B).

We conducted a series of experiments to determine the mechanism by which 5-HT increases phosphorylation of Thr 399 in synaptosomes. In vertebrates activation of S6 kinase by multiple pathways depends on PI-3 kinase activation (Dufner and Thomas, 1999). To determine whether 5-HT activated Thr 399 phosphorylation through PI-3 kinase, we examined the effects of a PI-3 kinase inhibitor (LY294002). LY294002 significantly decreased phosphorylation of S6 kinase at Thr 399 (Figs. 5C, quantitated in 6A). However, the effect of 5-HT on LY294002-treated synaptosomes was not blocked, because 5-HT increased Thr 399 phosphorylation, even in the presence of LY294002 (Figs. 5B, quantitated in 6B). Thus, 5-HT does not activate phosphorylation of S6 kinase through activation of PI-3 kinase.

An increase in translation mediated by 5-HT in pleural ganglia was blocked by rapamycin (Yanow et al., 1998). This increase was also blocked by inhibitors of PKA and PKC (Yanow et al., 1998). To determine whether this inhibition could be attributable to inhibition of S6 kinase, we determined the effect of PKA and PKC inhibitors on 5-HT-mediated phosphorylation of Thr 399. Both inhibitors blocked the ability of 5-HT to increase S6 kinase phosphorylation (Figs. 5C, quantitated in 6A, B).

One model of S6 kinase activation is that the rapamycin-sensitive protein FRAP acts to inhibit a constitutively active

Reference

Aplysia

Figure 4. Characterization of the Aplysia S6 kinase. A, The antibody to S6 kinase recognizes an ~60 kDa protein in both Aplysia nervous system (20 μg of homogenate) and SF9 cells infected with a baculovirus encoding Aplysia S6 kinase. No immunoreactivity is seen in uninfected SF9 cells. B, S6 kinase is enriched in synaptosomes; 10 μg from each fraction of a synaptosome preparation (H, homogenate; P1, P2, P3, and S2) were loaded on a gel and blotted for S6 kinase. The fraction most enriched for synaptosomes (P3) contained the highest levels of S6 kinase. C, Optimizing gel separation and running time reveals multiple immunoreactive bands in ganglia (20 μg of homogenate) and band(s) in SF9 cells that comigrate with the faster migrating band(s) from nervous system.
phosphatase (Weng et al., 1995b; Peterson et al., 1999). Thus, a phosphatase inhibitor should mimic the actions of FRAP. This phosphatase has been reported to be particularly sensitive to the phosphatase inhibitor calyculin-A (Parrott and Templeton, 1999), and indeed, the calyculin-A-sensitive phosphatase 2A has been reported to associate with S6 kinase (Peterson et al., 1999). We found that treating synaptosomes with calyculin-A led to a large increase in Thr 399 phosphorylation (Figs. 5D, quantitated in 6A). This increase occluded the ability of 5-HT to further increase Thr 399 phosphorylation. Indeed, in the presence of calyculin-A, 5-HT now led to a decrease in Thr 399 phosphorylation (Figs. 5D, quantitated in 6B).

To determine whether the phosphatase was upstream or downstream of FRAP, we determined whether the effect of calyculin-A could be blocked by rapamycin. The effect of calyculin-A was insensitive to treatment with rapamycin (10 ± 12%, effect of rapamycin on calyculin-treated synaptosomes; n = 3; SEM) (Fig. 5E); thus, the evidence suggests that a calyculin-A-sensitive phosphatase is downstream of FRAP in Aplysia synaptosomes.

5-HT increases S6 kinase activity
Although phosphorylation of the PDK-2 site is very closely linked with activation of the kinase (Weng et al., 1998), we wanted to confirm that 5-HT increased S6 kinase activity in synaptosomes. The consensus site for S6 kinase is R/KxR/KxxS (Flootow and Thomas, 1992), and there are two sites in Aplysia S6 that match this consensus (Fig. 2). To determine whether 5-HT increased S6 kinase activity, in vitro kinase assays using peptides derived from the Aplysia S6 sequence were accomplished after immunoprecipitation of S6 kinase from synaptosomes. These assays revealed a low level of basal S6 kinase activity that was significantly increased by 5-HT (Fig. 7). This increase was specific to S6 kinase because 5-HT did not increase kinase activity if preimmune serum was used for the immunoprecipitation (Fig. 7).

5-HT increases the level of S6 and S6 phosphorylation in synaptosomes
To observe whether activation of S6 kinase led to an increase in phosphorylation of endogenous S6, we raised an antibody to S6. This antibody recognized multiple bands migrating around the expected molecular weight of 31 kDa (Fig. 8A). It is well known that phosphorylation of S6 causes a shift in the migration of the protein (Thomas et al., 1979; Martin-Perez and Thomas, 1983). Treatment of synaptosomes with 5-HT increased the percentage of slower migrating S6, consistent with an increase in S6 phosphorylation (Fig. 8C). This increase was not seen in the presence of rapamycin (Fig. 8A, quantitated in C). Strikingly, in many experiments, 5-HT also induced a large rapamycin-sensitive increase in the level of S6 in synaptosomes (Fig. 8B, quantitated in D). Interestingly, the two effects of 5-HT were inversely correlated (Fig. 8E). When a large increase in phosphorylation was seen, there was little change in the abundance of S6 (Fig. 8A), and similarly, when there was a large increase in abundance, there was a smaller increase in the relative level of the upper band (Fig. 8B). This is consistent with 5-HT-induced production or stabilization of unphosphorylated S6.
**Apysia PDK-1 binds to and phosphorylates Aplysia S6 kinase**

We were interested in determining whether *Aplysia* PDK-1 was the primary regulator of Thr 399 phosphorylation. It has been suggested that PDK-1 not only phosphorylates the PDK-1 site (*Aplysia* Thr 239) but also phosphorylates the PDK-2 site (*Aplysia* 399) (Balendran et al., 1999). First, we determined whether *Aplysia* S6 kinase could bind to *Aplysia* PDK-1, because PDK-1 binds to many of its substrates (Belham et al., 1999). Indeed, GST fusion proteins of either PDK-1 or a mutant in which the catalytic lysine was converted to asparagine [PDK-1 (K-N)] bound to baculovirus-expressed S6 kinase, whereas no binding was seen with GST alone (Fig. 9A). However, we were unable to detect kinase activity from these GST fusion proteins. Therefore, to determine whether PDK could phosphorylate S6 kinase, we took advantage of the fact that, in SF9 cells, overexpressed S6 kinase was primarily unphosphorylated (Fig. 4C). Thus, we constructed baculovirus vectors for both PDK and PDK (K-N) and expressed PDK in SF9 cells (Fig. 9B).

Coexpression of *Aplysia* PDK with *Aplysia* S6 kinase in baculovirus was sufficient to cause a quantitative shift in the molecular weight of S6 kinase (Fig. 10A, quantitated in C). The mobility shift required active PDK because no shift was seen after expression with PDK (K-N) (Fig. 10A, quantitated in C). Because PDK phosphorylation in cells may require PI-3 kinase activity (Alessi et al., 1998; Pullen et al., 1998), we also tested overexpression of a baculovirus encoding constitutively active PI-3 kinase. This construct increased PI-3 kinase activity at least 10-fold in SF9 cell membranes (data not shown). There was no additional shift in S6 kinase when PI-3 kinase was expressed with PDK (Fig. 10A, quantitated in C).

**Figure 8.** 5-HT increase S6 phosphorylation and the amount of S6 in synaptosomes. Synaptosomes were treated with Ca$^{2+}$-free seawater or Ca$^{2+}$-free seawater and 20 μM 5-HT for 25 min in the presence or absence of 20 nM rapamycin. Samples were immediately put in Laemmli’s buffer, boiled, separated on SDS-PAGE gels, transferred to nitrocellulose, and blotted with the antibody to *Aplysia* S6. Two experiments are shown, one to illustrate the increase in the percentage in the upper band (A) and the other to illustrate the increase in S6 levels (B). C, Quantitation of the percentage change ((experimental – control)/control) * 100) in the amount of S6 phosphorylated. The amount of phosphorylation was determined by dividing the immunoreactivity in the upper band by the total immunoreactivity (upper plus lower band). This was then compared with the synaptosomes from the same preparation treated with only Ca$^{2+}$-free seawater (control); n = 6; SEM. *p < 0.05, comparisons between the control and the experimental condition; Student’s paired t test. D, Quantitation of changes in the level of S6 in synaptosomes. Levels of S6 were first standardized to the total protein loaded in the lane measured using ponceau staining. Because all lanes from one preparation are aliquots, there was never more than a 20% difference between total levels of proteins in lanes from the same experiment. Each experimental value was then compared with the synaptosomes from the same preparation treated with only Ca$^{2+}$-free seawater (control); n = 6; SEM. *p < 0.05, comparisons between the control and the experimental condition; Student’s paired t test. E, The change in level of S6 and the change in the phosphorylation of S6 from each preparation of synaptosomes were compared. The increase in phosphorylation and increase in amounts were inversely correlated, suggesting a specific increase in nonphosphorylated S6.

**Figure 9.** Characterization of *Aplysia* PDK-1. A, GST-PDK-1 binds to S6 kinase. Extracts from SF9 cells expressing S6 kinase were incubated with glutathione beads containing equal amounts of GST-PDK-1, GST-PDK-1 (K-N), and 10 times higher levels of GST. Glutathione beads were washed and then eluted with sample buffer, and the eluate were separated on a SDS-polyacrylamide gel, transferred to nitrocellulose, and blotted with the antibody to S6-kinase. Ten percent of the starting material was loaded in lane 1 (Start). B, Expression of PDK-1 and PDK-1 (K-N) in SF9 cells. Extracts of SF9 cells infected with PDK, PDK (K-N), or uninfected cells were separated on SDS-polyacrylamide gels, transferred to nitrocellulose, and blotted with the antibody to PDK-1.

**PDK-1 modulates threonine 399 phosphorylation in SF9 cells**

To determine whether the shift in migration was attributable to phosphorylation at Thr 399, we reprobed experiments examining coexpression of PDK and S6 kinase with the phospho-specific...
Figure 10. Aplysia PDK-1 phosphorylates Aplysia S6 kinase in SF9 cells. A. Coexpression of PDK-1 with S6 kinase in SF9 cells led to a quantitative shift in S6 kinase migration. Extracts from SF9 cells infected with the viruses shown were separated on SDS-polyacrylamide gels, transferred to nitrocellulose, and blotted for S6 kinase. B. The blot displayed in A was stripped and reprobed with the phospho-specific antibody to Thr 399 (B). When multiple infections are done, less of each virus is expressed as they all use the same promoter. Thus, we attempted to equalize the levels of S6 kinase by loading increasing levels of SF9 cell extract for multiple infections (10 μl, single infections; 20 μl, double infections; 30 μl, triple infections). Although only partially successful, neither of our quantitative results rely on equal loading of the gels. C. Quantitation of the shift in migration. The percentage of kinase in the slower migrating band was divided by the total immunoreactivity. SEM; n = 4. D. The immunoreactivity to the p-Thr-399 antibody was standardized by the immunoreactivity to the total S6 kinase antibody. All results are standardized to the coinfection with PDK-1 and S6 kinase run on the same gel. SEM; n = 4

Figure 11. A model for S6 kinase activation in Aplysia. Steps involved in phosphorylation of Thr 239 (PDK-1 site) are shown. Arrows indicate positive modulation. Lines with bars are negative modulations. The place which pharmacological agents act is indicated. Multiple arrows indicate missing steps. The dashed arrow between PDK-1 and the PDK-2 site indicates an indirect modulation, and the dashed arrow between FRAP and the PDK-2 site indicates the possibility that FRAP directly phosphorylates this site.

Antibody to the PDK-2 site. Coinfection with PDK led to an increase in phosphorylation at Thr 399, and this was associated with an additional shift in migration (Fig. 10B, quantitated in D). Thus, the initial quantitative shift in migration was probably attributable to phosphorylation of the PDK-1 site, Thr 239. Coinfection with a constitutively active PI-3 kinase virus further increased Thr 399 phosphorylation (Fig. 10B, quantitated in D) and led to some additional immunoreactivity that migrated at a lower position that may represent S6 kinase phosphorylated only at Thr 399. However, even under these conditions, very little protein was phosphorylated at Thr 399, because immunoreactivity with the S6 kinase antibody could only be seen comigrating with anti-phospho-Thr 399 immunoreactivity with very long exposures (data not shown). This is in contrast to the quantitative shift in mobility seen with the total antibody to S6 kinase, presumably by complete phosphorylation of Thr 239 (Fig. 10A). Moreover, coinfection with the kinase-inactive PDK also increased Thr 399 phosphorylation in the presence of PI-3 kinase (Fig. 10B, quantitated in D). However, in this case, all of the Thr 399 phosphorylation was seen in a faster migrating band, consistent with the lack of phosphorylation at the PDK-1 site. This faster migrating Thr 399-phosphorylated band was never seen in the nervous system, in which Thr 399 phosphorylation was only observed in the slowest migrating band.

These results suggest that PDK can phosphorylate S6 kinase. PDK also increases phosphorylation at the PDK-2 site, but this is indirect and does not require kinase activity. The increased phosphorylation of Thr 399 may be attributable to modulating the availability of S6 kinase to an endogenous kinase because of binding of S6 kinase to PDK-1.

DISCUSSION

Activation of S6 kinase in Aplysia

Our results suggest a model for S6 kinase activation by 5-HT in Aplysia (Fig. 11). Application of 5-HT, through activation of PKA and PKC, increases FRAP activity. FRAP then inactivates a phosphatase that had been constitutively dephosphorylating Thr 399. This leads to increased phosphorylation of Thr 399 and increased activity of S6 kinase. This pathway does not require PI-3 kinase activity. Similarly, phorbol ester-induced activation of S6 kinase phosphorylation is rapamycin-sensitive but PI-3 kinase-independent in HEK 293 cells (Herbert et al., 2000).

Thr 399 phosphorylation may also requires previous phosphorylation at the Thr 239 (PDK-1 site), because in synaptosomes, only a single Thr 399 phosphorylated band was seen that comigrates with the slowest migrating band. This is consistent with results from vertebrate S6 kinase (Weng et al., 1998). LY249002, an inhibitor of PI-3 kinase, decreased Thr 399 phosphorylation, possibly through inhibition of Thr 239 phosphorylation or through inhibition of the PDK-2 kinase. Phosphorylation at Thr 239 is probably attributable to phosphorylation by Aplysia PDK-1...
because, in SF9 cells, coinfusion of PDK-1 was sufficient to quantitatively shift the migration of S6 kinase.

The PDK-2 kinase is still unidentified, although there is some data suggesting that it is FRAP itself (Burnett et al., 1998a; Isotani et al., 1999). It is unlikely that 5-HT activates S6 kinase by stimulating this kinase. Indeed, in the presence of calyculin-A, 5-HT decreased Thr 399 phosphorylation, consistent with a possible 5-HT-mediated inhibition of the kinase that phosphorylates the PDK-2 site. We have not yet monitored phosphorylation of other important phosphorylation sites in S6 kinase (Fig. 1), and it is possible that 5-HT modifies phosphorylation of these sites as well.

The regulation of S6 kinase in *Aplysia* synaptosomes shares similarities with its activation in cell lines. Similar to our results, phosphorylation of the PDK-2 site is only seen in the slowest migrating form of S6 kinase (Weng et al., 1998). Thr 399 phosphorylation is highly rapamycin-sensitive in both systems (Weng et al., 1998), and there appear to be an important role for phosphatase regulation in both systems (Peterson et al., 1999). Also, PDK appears to be an upstream kinase in both *Aplysia* and vertebrates (Alessi et al., 1998; Pullen et al., 1998). The major difference is that activation of PI-3 kinase is not rate-limiting for Thr 399 phosphorylation (Weng et al., 1995a; Gingras et al., 1998; Balendran et al., 1999; Nave et al., 1999). There are a number of plausible explanations for this difference, including different basal levels of PI-3 kinase levels in synaptosomes, alternative pathways of activating FRAP, or alternative regulation of the PDK-2 kinase.

**The target of rapamycin**

Our results are consistent with the rapamycin-sensitive step required for the retention of long-term facilitation corresponding to activation of S6 kinase. However, there are other targets for the rapamycin-sensitive enzyme FRAP that also may play a role in the retention of long-term facilitation. Phosphorylation of eIF4E-BPs is mediated by FRAP (Brunn et al., 1997). This phosphorylation releases free eIF4E (Lin et al., 1994; Pause et al., 1994), which then can translocate mRNAs to the ribosome. A specific set of mRNAs that have structured 5′ untranslated regions are particularly sensitive to the levels of free eIF4E (Rosenwald et al., 1995; Rousseau et al., 1996). Recently, phosphorylation of a site equivalent to the PDK-2 site in Ca2+-independent PKCs was reported to also be rapamycin-sensitive (Parekh et al., 1999). This site is conserved in the Ca2+-independent PKC Apl II in *Aplysia*. It will be interesting to determine whether these proteins are also regulated in a rapamycin-sensitive manner in *Aplysia* neurons.

There are also important aspects of translational regulation at synapses that are independent of rapamycin (Yanow et al., 1998; Casadio et al., 1999). Regulation of translation at synapses is likely to involve multiple independent mechanisms. These include regulation of poly-A addition to mRNAs (Wu et al., 1998), increases in translation initiation (Weiler et al., 1994), and regulation of translation elongation (Scheetz et al., 1997, 2000).

**Role for an increase in the presence of translation factors**

5-HT increased S6 kinase activity. We observed both an increase in S6 kinase activity and the percentage of more slowly migrating S6 after addition of 5-HT. We also observed an increase in the levels of S6. Although this may be partially attributable to new synthesis of S6 (S6 is a protein whose translation is normally under regulation of S6 phosphorylation), it may also be that S6 is labile in our preparation, and 5-HT induces change in the conformation or localization of S6 that protects it from degradation.

Activation of the S6 kinase pathway leads to increases in translation of ribosomal proteins and translation factors (Dufner and Thomas, 1999). The increase in ribosomal proteins, such as S6, is unlikely to play an important role in synapse-specific plasticity, because ribosomes are assembled in the nucleus, and any protein made at a synapse would have to translocate back to the nucleus to have any effect on ribosome synthesis. However, the increase in translation factors, such as eIF1α and eIF2α, could play an important role in the rapamycin sensitivity of long-term memory. Indeed, preliminary evidence suggests that eIF1α mRNA is translocated to processes, and antibodies against eIF1α block the retention of long-term facilitation (Hegde et al., 1999). This is consistent with a model in which rapamycin-sensitive translation of translation factors at synapses is crucial for retention of long-term facilitation. This increase in translation factors could lead to a sustained increase in the translational capacity of the synapse, and this may be responsible for the retention of new varicosities by both increasing translation of RNAs that are at the synapse and RNAs that are emanating from the nucleus. Muta-

**REFERENCES**


